本帖最后由 老马 于 2012-1-13 21:20 编辑 2 L/ K+ I$ x' ~) ~- N4 W' {/ u/ a
( ~1 O- }$ L2 K* p. X# E
爱必妥和阿瓦斯丁的比较
. ?& D" z" j. a4 R1 t% @4 {: R
% N: l. {6 y3 p; Q3 `7 F
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ O5 Q( |5 a/ D, Y0 n
- [0 `2 b3 y9 I( L8 N5 u0 K
* c0 _5 u6 a3 m
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. K) Q8 \) |5 I: ?- Z0 t& g3 }4 m* f
==================================================
9 O3 @4 Q! L7 ?) W; ~! \/ M- B# bOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 ^7 F9 x9 R) |& m* Q8 Y( ?/ @
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% {( z9 H( W* z! i9 c' q/ w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! I1 f8 j5 i# x2 Z) D' X9 K" W6 y j5 H
|